IPO Databook: InventisBio Co., Limited（） (688382 HK) - Aug 2026

107 Views23 Aug 2026 10:18

SUMMARY

InventisBio Co., Limited, founded in 2013, is a biopharmaceutical company focused on oncology, autoimmune, and metabolic disorders with eight product candidates. It is seeking a primary HKEX Main Board listing.
Two Core Products, D-2570 and taragarestrant, are in Phase III clinical trials. Two assets, befotertinib and garsorasib, are approved in China and included in NRDL.
The company reported a loss of RMB(240,204) in 2024 and RMB(316,865) in 2025. Net cash used in operating activities was RMB(241,972) in 2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream